Dizal to Present Nine Abstracts Across Its Hematology Portfolio at EHA 2026

Golidocitinib: Expanding the Treatment Landscape in PTCL   Golidocitinib is currently the world’s first and only Janus kinase 1 (JAK1) inhibitor approved for the treatment of relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).    Multiple clinical studies are ongoing to evaluate golidocitinib as a single agent as well as in combination to treat first-line and r/r PTCL patients. Promising results for some rare PTCL subtypes will be presented as well. At this year’s EHA Congress, latest results will be reported in eight abstracts.   Birelentinib: Broadening Therapeutic Potential in DLBCL   Birelentinib (DZD8586) is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration. By simultaneously inhibiting both BTK and LYN signaling pathways, birelentinib is designed to block both BTK-dependent as well as BTK-independent B cell signaling pathways. Previously reported data show that birelentinib monotherapy exhibits promising antitumor activity in r/r DLBCL, with comparable tumor responses observed in both GCB and non-GCB subtypes, alongside a manageable safety profile.    The new data to be presented at EHA 2026 further demonstrate birelentinib’s durable activity across molecular subtypes, supporting its potential as a differentiated treatment option for patients with DLBCL.      Dizal presentation details during EHA 2026：     Lead Author Abstract Title Presentation Details Prof. Wei Zhang Golidocitinib Combined with CHOP in Newly-Diagnosed Peripheral T-Cell Lymphoma: Preliminary Results from a Phase 1/2 Clinical Trial (JACKPOT 53) Abstract#PS2129 Poster Session June 13, 2026, 18:45-19:45 CEST Prof. Ting Niu Exceptional Efficacy and Manageable Safety of Golidocitinib Combined with CHOP as First-Line Treatment for Peripheral T-Cell Lymphoma (JACKPOT52): Preliminary Results from a Phase I/II Study Abstract#PS2152  Poster Session June 13, 2026, 18:45-19:45 CEST Prof. WenYu Li Golidocitinib-Based Combination Therapy as First-Line Treatment for PTCL: A Single-Center Retrospective Analysis (JACKPOT55) Abstract# PB3878 Online Publication May 12, 2026, 15:30 CEST Prof. Zhiming Li Safety and Preliminary Efficacy of Golidocitinib Combined with Pomalidomide in Relapsed or Refractory Peripheral T-Cell Lymphoma (JACKPOT25): A Multicenter, Phase I/II Study Abstract# PS2158  Poster Session June 13, 2026, 18:45-19:45 CEST Prof. Qingqing Cai Golidocitinib and Liposomal Mitoxantrone for Relapsed/Refractory Peripheral T-Cell Lymphoma: Preliminary Safety and Efficacy from a Multi-Center Retrospective Study Abstract# PB3851  Online Publication May 12, 2026, 15:30 CEST Prof. Lugui Qiu Birelentinib Demonstrates Manageable Safety Profile and Universal Antitumor Activity Across Molecular Subtypes in Diffuse Large B Cell Lymphoma Abstract#PF973 Poster Session June 12, 2026, 18:45-19:45 CEST Prof. Zhao Wang Golidocitinib Monotherapy in Hemophagocytic Lymphohistiocytosis: A Prospective, Single-Arm Clinical Trial to Evaluate Efficacy and Safety (JACKPOT11) Abstract#PF700 Poster Session June 12, 2026, 18:45-19:45 CEST Prof. Shuhua Yi Preliminary Efficacy and Safety of Golidocitinib in Relapsed/Refractory T Cell and NK Cell Large Granular Lymphocyte Leukemia Abstract#PF1031 Poster Session June 12, 2026, 18:45-19:45 CEST Prof. Rong Tao A Novel Triplet Regimen of Tislelizumab, Golidocitinib, and Selinexor for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma: Preliminary Safety and Efficacy from a Phase Ib/II Study Abstract#PS2149 Poster Session June 13, 2026, 18:45-19:45 CEST   About Golidocitinib (DZD4205) Golidocitinib is currently the first and only Janus kinase 1 (JAK1) inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).  At the data cut-off date of August 31, 2023, golidocitinib has demonstrated robust and durable anti-tumor efficacy, with an ORR of 44.3%. All subtypes benefited well, and the ORR of common subtypes exceeded 40%. More than 50% of the patients with tumor remission achieved a complete response with a CRR of 23.9%. Per IRC assessment, the median duration of response (mDoR) reached 20.7 months. As of February 2024, golidocitinib showed a median overall survival (mOS) of 24.3 months.  Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published in Annals of Oncology (Impact Factor: 51.8), and global pivotal trial data of golidocitinib for the treatment of r/r PTCL (JACKPOT PART B) were published in The Lancet Oncology (Impact Factor: 54.4).   About Birelentinib (DZD8586) Two resistance mechanisms have been found in patients whose diseases have progressed on a BTK inhibitor treatment: the BTK C481X mutation and BTK-independent BCR signaling pathway activation. Birelentinib is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration, designed to treat both BTK-dependent and BTK-independent B-cell non-Hodgkin lymphoma (B-NHL). In August 2025, birelentinib was granted Fast Track Designation by the U.S. FDA for the treatment of adult patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.   About Dizal Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio. ZEGFROVY is the first and only small molecule drug approved in both the U.S. and China, for the treatment of non-small cell lung cancer with EGFR exon20 insertion mutations. Golidocitinib has been approved in China for the treatment of relapsed and refractory PTCL. To learn more about Dizal, please visit www.dizalpharma.com, or follow us on Linkedin or X.   Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, and “intend” and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal’s competitive environment, and political, economic, legal, and social conditions. Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.   Contacts Investor Relations: [email protected] Business Development: [email protected] Media Contact: [email protected]

The release as fetched from its publisher. dizalpharma.com ↗